MedPath

Allergan, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
10.5K
Market Cap
-
Website
https://thespotlyte.com/index.html

Clinical Trials

18

Active:8
Completed:2

Trial Phases

4 Phases

Phase 1:4
Phase 2:2
Phase 3:5
+1 more phases

Drug Approvals

191

CANADA:63
FDA:62
SFDA:2
+1 more agencies

Drug Approvals

Bimatoprost Ophthalmic Solution

Product Name
卢美根
Approval Number
H20150485
Approval Date
Jun 10, 2020
NMPA

Clinical Trials

Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials

Phase 3
5 (35.7%)
Phase 1
4 (28.6%)
Not Applicable
3 (21.4%)
Phase 2
2 (14.3%)
No trials found

News

Allergan Botox Patent Infringement Trial Against Revance Set for July in Delaware

A Delaware federal judge has ruled that Allergan's patent infringement lawsuit against Revance Therapeutics will proceed to trial in July 2024, following the denial of summary judgment motions from both parties.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.